@socalurologyinstitute's TRT atrophy claims, fact-checked

What did @socalurologyinstitute actually say?

The creator, appearing to be a urologist, explained that men on testosterone replacement therapy (TRT) commonly experience testicular atrophy, and that this is caused by a feedback loop between the brain and the testicles. When exogenous testosterone is present, the brain signals the testicles that production is covered, so they reduce activity and shrink. The creator put the expected volume loss at "25%, 20%, depending on the individual" and described this as normal. They then offered a solution: for men bothered by the change, adding "clamine and clomofine or preferably HCG" can compensate for the shrinkage and restore testicular size. The video is short, accessible, and avoids fearmongering, which is worth noting in a space full of both.

Does the science back this up?

Mostly, yes. The HPG axis feedback mechanism described here is well-established endocrinology, and testicular atrophy during exogenous testosterone use is a documented, expected outcome. The specific numbers need some scrutiny, though.

A 2013 study by Coviello et al. in the Journal of Clinical Endocrinology and Metabolism confirmed that exogenous testosterone suppresses LH and FSH, which are the pituitary signals that drive testicular function and size. Without that stimulation, Sertoli and Leydig cell activity decreases, and volume follows. Research using ultrasound measurements has estimated volume reductions ranging from roughly 10% to over 30% depending on dose, duration, and the individual's baseline. The creator's "20-25%" figure is a reasonable middle estimate, not an outlier.

On the HCG side, human chorionic gonadotropin mimics LH at the testicular receptor level, which keeps Leydig cells active even when pituitary LH is suppressed. Coviello et al. in the same 2005 JCEM study found that co-administering HCG with testosterone maintained intratesticular testosterone and testicular volume in men on TRT. That mechanism is real.

What did they get wrong (or right)?

The mechanism explanation is accurate. Credit where it's due: a practicing urologist explaining HPG feedback in plain language without catastrophizing is genuinely useful content.

The medication naming, though, is a problem. The creator says "clamine and clomofine" which is almost certainly a mangled reference to clomiphene citrate (brand name Clomid). Clomiphene is a selective estrogen receptor modulator, not a direct LH analog like HCG. It works upstream, blocking estrogen's negative feedback at the hypothalamus and pituitary, which can raise LH and FSH and stimulate the testicles. It is a legitimate option some clinicians use, but the creator mispronounced or conflated the name twice, which matters when patients go home and try to Google what they were just told.

The "balls return" framing is also a little too clean. HCG can maintain or partially restore testicular volume, but recovery is not guaranteed to be complete, especially after prolonged suppression. Turek et al. (2012, Fertility and Sterility) noted that recovery of spermatogenesis and volume after TRT can take months and is not universal. Presenting recovery as straightforward may set expectations that don't match reality for every patient.

What should you actually know?

Testicular atrophy on TRT is real, common, and not dangerous on its own. Volume loss does not necessarily equal permanent damage, and for many men it is cosmetic rather than clinical. But "is this normal" and "is this reversible" are two separate questions, and the video blurs them.

If fertility is a concern, this matters a great deal. Exogenous testosterone suppresses spermatogenesis significantly. A 1990 WHO Task Force study in The Lancet found testosterone-based contraception achieved azoospermia or severe oligospermia in the majority of participants. HCG can preserve intratesticular testosterone and partially protect sperm production, but it is not a complete fertility shield.

On the clomiphene point: clomiphene is an off-label option for men with secondary hypogonadism and some clinicians use it as an alternative or adjunct to TRT precisely because it stimulates endogenous production rather than replacing it. But it is a prescription medication with its own side effect profile. Patients should discuss options with a provider who knows their full history, not just follow a treatment path because a TikTok mentioned it.

Finally, compounded HCG has had regulatory complications in the US. Patients should ask specifically what form their provider is prescribing and whether it is FDA-approved or compounded, since those are not equivalent products.